Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (676)	8/31/2002 12:08:02 AM
From: Miljenko Zuanic	Respond to of 3560

Abstract deadline was in mid June, so maybe too early for PI data. They may have preclinical data abstract and early data from PI can be attached at presentation. I do know that they expanded PI from single site (common for PI) with two new centers, in May. At this point (few next months) it will be forthcoming to learn about Avastin breast/colorectal trials. Regardless that REGN trap may be different story, after Iressa news market will not take easy another disappointing news on new cancer drugs. <<Really promising news could take some of the valuation pressure off axokine.>> Shorts continue to attack, I guess, based on potential problems with Axokine. If company start IL-1 trap before 1Q 03 (and maybe trap partner become reality) and with preliminary result of the IL-4/13 safety they will start to think about opposite outcome. I continue to believe that Axokine will satisfy regulatory requirement, but that is another story. Miljenko